Abstract
AbstractWhereas best practice of clinical prediction of human phenotypes by polygenic risk score (PRS) has yet to be fully implemented, commercial industries already offer pre-implantation genetic testing for PRS (PGT-P) to select embryos with ‘desirable’ potential. However, its efficacy is questionable due to the current technical challenges, which also raise ethical concerns. Ourin-silicosimulations utilizing biobank resources revealed that the embryo selected by PGT-P substantially differs depending on the choice of methods and the random fluctuation of the PRS construction. Here, we outline the technical challenges and also the ethical concerns that remain even if the technical challenges are solved, and hope to call on a society-wide discussion for this technology.
Publisher
Cold Spring Harbor Laboratory